ERBB2 and breast carcinoma: In gene expression-based breast cancer classification, it is known that the prognosis of the HER2 overexpression group (estrogen receptor−, HER2+) can improve with targeted therapy, and the basal type group (estrogen receptor−, HER2−) has many early recurrences and poor prognoses [16].